Hervé Affagard, MaaT Pharma CEO
One year into clinical hold, FDA has more questions about 'pooled' microbiome therapy
The FDA is still wary about a trial testing a microbiome therapy in patients with steroid-resistant acute graft-versus-host disease (aGVHD).
A year after MaaT Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
